<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02165332</url>
  </required_header>
  <id_info>
    <org_study_id>NP29334</org_study_id>
    <nct_id>NCT02165332</nct_id>
  </id_info>
  <brief_title>A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval</brief_title>
  <official_title>A Two-part, Single-center, Single-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Four-way Crossover Study to Investigate the Effect of RO7033877 on the QT/QTc Interval in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a two-part study to evaluate the safety and tolerability of supratherapeutic doses of&#xD;
      RO7033877 (Part 1) and to investigate the effect of RO7033877 on the QTc interval in healthy&#xD;
      volunteers (Part 2). Part 1 is a single ascending dose, randomized, observer-blind,&#xD;
      placebo-controlled study to determine the safety tolerability and pharmacokinetics of a&#xD;
      supratherapeutic dose to be used in Part 2. Participants will be randomized in up to 8&#xD;
      cohorts to receive a single dose of either RO7033877 or placebo. Part 2 will be a single&#xD;
      dose, randomized, double-blind, double dummy, placebo-controlled, positive control, 4-way&#xD;
      crossover study. Part 2 will evaluate whether a single therapeutic or supratherapeutic dose&#xD;
      of RO7033877 has a threshold pharmacologic effect on cardiac repolarization, as detected by&#xD;
      changes in the QT/QTc interval measured by electrocardiogram (ECG). Pharmacokinetic&#xD;
      parameters will be assessed for Parts 1 and 2, continuous ECG recordings will be evaluated in&#xD;
      Part 2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Incidence of adverse events (AEs) after single, supratherapeutic dose of RO7033877</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Pharmacokinetic parameters derived from plasma and urine concentrations, single dose of RO7033877: Area under the curve (AUC)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Continuous, 12-lead Holter electrocardiogram (ECG) recordings</measure>
    <time_frame>Day -1 and 1 of each Period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs after single IV infusion of RO7033877</measure>
    <time_frame>Up to 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 only: Changes in other ECG parameters, descriptive analysis</measure>
    <time_frame>Up to 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 only: Changes in PK/PD relationships between any effect on ECG and RO7033877 plasma concentrations, descriptive analysis</measure>
    <time_frame>Up to 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Area under the concentration-time curve (AUC) of RO7033877</measure>
    <time_frame>Day 1 of each Period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution, given as a minimum of a 2 hour infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: RO7033877</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: RO7033877</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose 4-way crossover</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1: SAD RO7033877</intervention_name>
    <description>Single dose</description>
    <arm_group_label>Part 1: RO7033877</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1: SAD placebo</intervention_name>
    <description>Single dose</description>
    <arm_group_label>Part 1: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2: Treatment A, RO7033877</intervention_name>
    <description>Single dose RO7033877 and moxifloxacin placebo</description>
    <arm_group_label>Part 2: RO7033877</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2: Treatment B, RO7033877</intervention_name>
    <description>Single dose RO7033877 and moxifloxacin placebo</description>
    <arm_group_label>Part 2: RO7033877</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2: Treatment C, moxifloxacin</intervention_name>
    <description>Single dose moxifloxacin and RO7033877 placebo</description>
    <arm_group_label>Part 2: RO7033877</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2: Treatment D, RO7033877 and moxifloxacin placebo</intervention_name>
    <description>Single dose moxifloxacin placebo and RO7033877 placebo</description>
    <arm_group_label>Part 2: RO7033877</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female of non-childbearing potential participants, 18 to 65 years of&#xD;
             age, inclusive&#xD;
&#xD;
          -  Healthy status is defined as the absence of evidence of any clinically significant,&#xD;
             active, or chronic disease following a detailed medical and surgical history, a&#xD;
             complete physical examination and vital signs, 12-lead ECG, hematology, blood&#xD;
             chemistry, serology and urinalysis and confirmed by a creatinine clearance estimated&#xD;
             by formula of Cockcroft-Gault &gt; 80 mL/min/1.73 m2&#xD;
&#xD;
          -  Postmenopausal or surgically sterile females (bilateral oophorectomy or hysterectomy&#xD;
             performed at least 6 months prior to study participation)&#xD;
&#xD;
          -  A body mass index (BMI) between 18 and 30 kg/m2 inclusive and minimum body weight &gt;/=&#xD;
             50 kg, inclusive&#xD;
&#xD;
          -  For men with a female partner(s) of childbearing potential: agreement to use a barrier&#xD;
             method of contraception during the treatment period and for at least 3 months after&#xD;
             the last dose of study drug&#xD;
&#xD;
          -  Participants who are non-smokers, or former smokers who have not smoked for at least&#xD;
             45 days prior to screening (former smokers are to have a total of &lt; 10 pack year&#xD;
             smoking history)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Men with female partners who are lactating or are pregnant&#xD;
&#xD;
          -  History of any clinically significant disease, e.g. gastrointestinal, renal, hepatic,&#xD;
             cardiovascular, endocrine, hematologic or allergic disease(s), metabolic disorder,&#xD;
             cancer (may have had basal or squamous cell carcinoma of skin or cervix as long as&#xD;
             surgically removed or deemed cured by cryotherapy, laser therapy, conization, etc.,&#xD;
             with stability for the past 2 years)&#xD;
&#xD;
          -  Any major illness within one month before the first dose of study drug or any febrile&#xD;
             illness within one week prior to screening and up to first dose administration&#xD;
&#xD;
          -  Any prescribed medications taken within 4 weeks prior to first dosing or within 5&#xD;
             times the elimination half-life of the medication prior to first dosing (whichever is&#xD;
             longer)&#xD;
&#xD;
          -  Any preparations containing St. John's Wort taken within 4 weeks prior to first dosing&#xD;
&#xD;
          -  Any other over-the-counter medications, including vitamins or herbal remedies, taken&#xD;
             within 14 days prior to first dosing or within 5 times the elimination half-life of&#xD;
             the medication prior to first dosing (whichever is longer); acetaminophen is the only&#xD;
             exception&#xD;
&#xD;
          -  Taking any nutrients known to modulate cytochrome P450 (CYP) 3A activity. Participants&#xD;
             will be instructed to abstain from consuming grapefruit, Seville oranges, and&#xD;
             grapefruit- or Seville orange-containing products within 2 weeks prior to&#xD;
             administration of study drugs&#xD;
&#xD;
          -  Regular consumption of large amounts of caffeine or xanthine-containing substances&#xD;
             (e.g. &gt;/= 5 cups of coffee/day, tea, cola, Mountain Dew, chocolate, diet pills,&#xD;
             &quot;energy drinks&quot; or any other type of stimulant) or unable to refrain from consumption&#xD;
             of caffeine or xanthine-containing substances from 72 hours prior to each entry in the&#xD;
             clinic and during the in-house periods&#xD;
&#xD;
          -  Any medication that inhibits active tubular secretion (e.g. probenecid, H2 receptor&#xD;
             antagonists, trimethoprim) within 4 weeks prior to first dosing&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 60 days prior to&#xD;
             screening&#xD;
&#xD;
          -  Concomitant disease or condition that could interfere with, or treatment of which&#xD;
             might interfere with, the conduct of the study, or that would, in the opinion of the&#xD;
             investigator, pose an unacceptable risk to the subject in this study&#xD;
&#xD;
          -  History and/or family history of cardiac anomalies, e.g. congenital long QT syndrome,&#xD;
             unexplained syncope, or clinically significant abnormal ECG&#xD;
&#xD;
          -  ECG evidence at screening or baseline of, e.g. atrial fibrillation, atrial flutter,&#xD;
             complete right or left bundle branch block and/or clinically relevant prolongation of&#xD;
             the PR interval as determined by the Investigator&#xD;
&#xD;
        Exclusion criteria for Part 2 only:&#xD;
&#xD;
          -  History of allergy or sensitivity to moxifloxacin or other fluoroquinolones, and/or&#xD;
             history of tendon rupture when taking or considered time-wise related to consumption&#xD;
             of a fluoroquinolone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2014</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

